Immunome, Inc. (NASDAQ: IMNM), a biotechnology company focused on developing targeted cancer therapies, has announced a proposed public offering of its common stock. The company plans to issue and sell $400 million of shares of its common stock, with the potential for an additional $60 million of shares through the underwriters' 30-day option. The offering is being made pursuant to a shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission (SEC) on February 13, 2024.
The joint bookrunning managers for the proposed offering are Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs & Co. LLC, and Guggenheim Securities, while Wedbush PacGrow and LifeSci Capital are acting as co-lead managers.
Immunome is a clinical-stage targeted oncology company with a portfolio of therapeutics, including varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. The company is also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets.
This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor is there any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Immunome's announcement of the proposed public offering provides insight into its strategic financial decision-making and its plans to raise capital for advancing its pipeline of therapeutics. Today the company's shares have moved -12.1% to a price of $20.64. If you want to know more, read the company's complete 8-K report here.
